Skip to main content
OpenTrials

Clinical trial condition

Kidney Neoplasms

Explore clinical trials studying Kidney Neoplasms. Study availability and eligibility vary by location and protocol.

1,142 public trials 219 recruiting studies
Refine in advanced search Browse all conditions

Kidney Neoplasms trial results

Active, Not Recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +68 more
Locations
  • Exelixis Clinical Site #53 Gilbert, Arizona, United States
  • Exelixis Clinical Site #18 Phoenix, Arizona, United States
  • Exelixis Clinical Site #1 Duarte, California, United States
  • Exelixis Clinical Site #20 La Jolla, California, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

NCT04707248

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +24 more
Locations
  • Arizona Oncology Associates, PC HOPE (A)A HOPE) Tucson, Arizona, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • Florida Cancer Lake Mary Lake Mary, Florida, United States
  • Oklahoma University Oklahoma City, Oklahoma, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

NCT04522323

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +15 more
Locations
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Fort Myers, Florida, United States
  • Research Site St Louis, Missouri, United States
  • Research Site New York, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03141177

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Local Institution - 0077 Daphne, Alabama, United States
  • Local Institution - 0044 Goodyear, Arizona, United States
  • Local Institution - 0132 Tucson, Arizona, United States
  • Local Institution - 0133 Bakersfield, California, United States
View all 135 locations
View Trial Details
Active, Not Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

NCT05219318

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • CH de la Cote Basque - Service d'Oncologie Bayonne, France
  • CHU de Bordeaux - Service d'Oncologie Bordeaux, France
  • Centre François Baclesse - Service d'Oncologie Caen, France
  • Centre Jean Perrin - Service d'Oncologie Clermont-Ferrand, France
View all 26 locations
View Trial Details

Related conditions